Suppr超能文献

血管性血友病因子的个体内变异性及重复检测的必要性。

Intraindividual variability of von Willebrand factor and the need for repeated testing.

作者信息

Kirkeby Malene Helligsø, Højbjerg Johanne Andersen, Abildgaard Anders Mønsted, Larsen Julie Brogaard

机构信息

Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

出版信息

Res Pract Thromb Haemost. 2025 May 17;9(4):102889. doi: 10.1016/j.rpth.2025.102889. eCollection 2025 May.

Abstract

BACKGROUND

Diagnosing von Willebrand disease (VWD) is complicated by intraindividual variation of von Willebrand factor (VWF). Current guidelines define VWD as VWF antigen (VWF:Ag) or VWF activity of <0.30 or <0.50 × 10 IU/L depending on the presence of bleeding symptoms. However, there is no consensus on whether repeated testing is necessary in patients with VWF levels close to the cutoff.

OBJECTIVES

This study aimed to examine the intraindividual variation of VWF antigen (VWF:Ag), platelet-binding activity (VWF:GPIbR), and collagen-binding activity (VWF:CB) by use of routine patient data and to define cutoffs for reliably excluding VWD based on a single sample.

METHODS

In this cross-sectional study, we extracted patient results of VWF:Ag, VWF:GPIbR, and VWF:CB analyzed at the Department of Clinical Chemistry, Aarhus University Hospital, from January 2013 to January 2024 and calculated total and nonanalytical coefficient of variation (CV).

RESULTS

We found a CV of 22.03% ( = 252), 24.10% ( = 333), and 24.07 ( = 58) for VWF:Ag, VWF:GPIbR, and VWF:CB, respectively. We did not find substantial differences in CV across subgroups based on sex, age, and VWF levels. Furthermore, we estimated a method-specific cutoff to exclude VWD based on a single blood sample at 0.67 × 10 IU/L, 0.66 × 10 IU/L, and 0.88 × 10 IU/L for VWF:Ag, VWF:GPIbR, and VWF:CB, respectively.

CONCLUSION

We found considerable intraindividual VWF variation in patients referred for VWF testing. Our results confirm that repeated testing is crucial when VWF is low in the normal range to prevent false rejection of a true VWD diagnosis.

摘要

背景

血管性血友病因子(VWF)的个体内变异使血管性血友病(VWD)的诊断变得复杂。当前指南将VWD定义为根据出血症状的有无,VWF抗原(VWF:Ag)或VWF活性<0.30或<0.50×10 IU/L。然而,对于VWF水平接近临界值的患者是否需要重复检测,尚无共识。

目的

本研究旨在利用常规患者数据检查VWF抗原(VWF:Ag)、血小板结合活性(VWF:GPIbR)和胶原结合活性(VWF:CB)的个体内变异,并确定基于单个样本可靠排除VWD的临界值。

方法

在这项横断面研究中,我们提取了2013年1月至2024年1月在奥胡斯大学医院临床化学科分析的VWF:Ag、VWF:GPIbR和VWF:CB的患者结果,并计算了总变异系数和非分析变异系数(CV)。

结果

我们发现VWF:Ag、VWF:GPIbR和VWF:CB的CV分别为22.03%(n = 252)、24.10%(n = 333)和24.07(n = 58)。我们未发现基于性别、年龄和VWF水平的亚组间CV有实质性差异。此外,我们估计基于单个血样排除VWD的方法特异性临界值分别为VWF:Ag 0.67×10 IU/L、VWF:GPIbR 0.66×10 IU/L和VWF:CB 0.88×10 IU/L。

结论

我们发现接受VWF检测的患者存在相当大的个体内VWF变异。我们的结果证实,当VWF处于正常范围低值时,重复检测对于防止真正的VWD诊断被错误排除至关重要。

相似文献

5
Aural toilet (ear cleaning) for chronic suppurative otitis media.慢性化脓性中耳炎的耳道清理(耳部清洁)
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013057. doi: 10.1002/14651858.CD013057.pub3.
8
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
9
Prognostic factors for return to work in breast cancer survivors.乳腺癌幸存者恢复工作的预后因素。
Cochrane Database Syst Rev. 2025 May 7;5(5):CD015124. doi: 10.1002/14651858.CD015124.pub2.
10
Systemic antibiotics for chronic suppurative otitis media.用于慢性化脓性中耳炎的全身性抗生素
Cochrane Database Syst Rev. 2025 Jun 9;6(6):CD013052. doi: 10.1002/14651858.CD013052.pub3.

本文引用的文献

4
Von Willebrand Disease: Current Status of Diagnosis and Management.血管性血友病:诊断与管理的现状。
Hematol Oncol Clin North Am. 2021 Dec;35(6):1085-1101. doi: 10.1016/j.hoc.2021.07.004. Epub 2021 Aug 13.
9
Von Willebrand's Disease.血管性血友病
N Engl J Med. 2016 Nov 24;375(21):2067-2080. doi: 10.1056/NEJMra1601561.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验